These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 20660689)

  • 1. Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia.
    van Rensburg DJ; Perng RP; Mitha IH; Bester AJ; Kasumba J; Wu RG; Ho ML; Chang LW; Chung DT; Chang YT; King CH; Hsu MC
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4098-106. PubMed ID: 20660689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, multicenter Phase II study comparing the efficacy and safety of oral nemonoxacin with oral levofloxacin in the treatment of community-acquired pneumonia.
    Liu Y; Zhang Y; Wu J; Zhu D; Sun S; Zhao L; Wang X; Liu H; Ren Z; Wang C; Xiu Q; Xiao Z; Cao Z; Cui S; Yang H; Liang Y; Chen P; Lv Y; Hu C; Lv X; Liu S; Kuang J; Li J; Wang D; Chang L
    J Microbiol Immunol Infect; 2017 Dec; 50(6):811-820. PubMed ID: 26748734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicentre, randomised, double-blind, double-dummy, parallel-controlled, phase 3 clinical trial assessing the efficacy and safety of intravenous nemonoxacin malate vs. levofloxacin for community-acquired pneumonia in adult patients.
    Li Y; Zhu D; Sun S; Chang X; Cao Z; Yang Y; Fu X; Li X; Xu J; Zhu Y; Hui F; Xu X; Chen Z; Peng L; Ma Z; Mo B; Li C; Lv Y; Zhao L; Zhu G; He Y; Liu H; Chen J; Wang Y; Liang Y; Lu Y; Qin Z; Yang H; Zhang M; Wu S; Tong Z; Ye F; Xiao Z; Wang X; Qiu C; Kuang J; Huang H; Wang K; Ying K; Jin F; Lv X; Huang Y; Liu D; Wang W; Zhang Y
    Int J Antimicrob Agents; 2024 Aug; 64(2):107235. PubMed ID: 38851462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial.
    Yuan J; Mo B; Ma Z; Lv Y; Cheng SL; Yang Y; Tong Z; Wu R; Sun S; Cao Z; Wu J; Zhu D; Chang L; Zhang Y;
    J Microbiol Immunol Infect; 2019 Feb; 52(1):35-44. PubMed ID: 30181096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated safety summary of phase II and III studies comparing oral nemonoxacin and levofloxacin in community-acquired pneumonia.
    Cheng SL; Wu RG; Chuang YC; Perng WC; Tsao SM; Chang YT; Chang LW; Hsu MC
    J Microbiol Immunol Infect; 2019 Oct; 52(5):743-751. PubMed ID: 30616912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
    Bergallo C; Jasovich A; Teglia O; Oliva ME; Lentnek A; de Wouters L; Zlocowski JC; Dukart G; Cooper A; Mallick R;
    Diagn Microbiol Infect Dis; 2009 Jan; 63(1):52-61. PubMed ID: 18990531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia.
    Tanaseanu C; Milutinovic S; Calistru PI; Strausz J; Zolubas M; Chernyak V; Dartois N; Castaing N; Gandjini H; Cooper CA;
    BMC Pulm Med; 2009 Sep; 9():44. PubMed ID: 19740418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia.
    Gotfried MH; Dattani D; Riffer E; Devcich KJ; Busman TA; Notario GF; Palmer RN
    Clin Ther; 2002 May; 24(5):736-51. PubMed ID: 12075942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of nemonoxacin with special focus on clinical development.
    Qin X; Huang H
    Drug Des Devel Ther; 2014; 8():765-74. PubMed ID: 25045247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia.
    Bradley JS; Arguedas A; Blumer JL; Sáez-Llorens X; Melkote R; Noel GJ
    Pediatr Infect Dis J; 2007 Oct; 26(10):868-78. PubMed ID: 17901791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Nemonoxacin vs Levofloxacin in Patients With Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Control Trials.
    Khan AS; Iqbal A; Muhammad AA; Mazhar F; Lodhi MF; Ahmed KF; Kumar S; Varrassi G; Khatri M
    Cureus; 2023 Apr; 15(4):e37650. PubMed ID: 37200652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic Evaluation of Nemonoxacin, Moxifloxacin and Levofloxacin in the Treatment of Early Community-Acquired Pneumonia with Possible Pulmonary Tuberculosis.
    Zhao M; Chi Z; Pan X; Yin Y; Tang W
    Int J Environ Res Public Health; 2022 Apr; 19(8):. PubMed ID: 35457683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults.
    D'Ignazio J; Camere MA; Lewis DE; Jorgensen D; Breen JD
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4035-41. PubMed ID: 16189077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia.
    Oldach D; Clark K; Schranz J; Das A; Craft JC; Scott D; Jamieson BD; Fernandes P
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2526-34. PubMed ID: 23507282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential role of nemonoxacin for treatment of common infections.
    Huang CH; Lai CC; Chen YH; Hsueh PR
    Expert Opin Pharmacother; 2015 Feb; 16(2):263-70. PubMed ID: 25529577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. The Scandinavian Sparfloxacin Study Group.
    Ortqvist A; Valtonen M; Cars O; Wahl M; Saikku P; Jean C
    Chest; 1996 Dec; 110(6):1499-506. PubMed ID: 8989068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.
    File TM; Segreti J; Dunbar L; Player R; Kohler R; Williams RR; Kojak C; Rubin A
    Antimicrob Agents Chemother; 1997 Sep; 41(9):1965-72. PubMed ID: 9303395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
    Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
    Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia.
    Frank E; Liu J; Kinasewitz G; Moran GJ; Oross MP; Olson WH; Reichl V; Freitag S; Bahal N; Wiesinger BA; Tennenberg A; Kahn JB
    Clin Ther; 2002 Aug; 24(8):1292-308. PubMed ID: 12240780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
    Lin L; Chang LW; Tsai CY; Hsu CH; Chung DT; Aronstein WS; Ajayi F; Kuzmak B; Lyon RA
    Antimicrob Agents Chemother; 2010 Jan; 54(1):405-10. PubMed ID: 19884368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.